Cuprega 75mg Tablet SR

Introduction to Cuprega 75mg Tablet SR

Cuprega 75mg Tablet SR is a medication primarily used to manage certain types of pain and anxiety. It contains the active ingredient Pregabalin, which is known for its effectiveness in treating neuropathic pain, fibromyalgia, and generalized anxiety disorder.

Composition of Cuprega 75mg Tablet SR

The main component of Cuprega 75mg Tablet SR is Pregabalin. This ingredient works by interacting with specific calcium channels in the brain and spinal cord, helping to reduce the release of neurotransmitters that cause pain and anxiety.

Uses of Cuprega 75mg Tablet SR

Relief from neuropathic pain associated with nerve damage.
Management of fibromyalgia, a condition characterized by widespread musculoskeletal pain.
Treatment of generalized anxiety disorder to help reduce symptoms of anxiety.

Side effects of Cuprega 75mg Tablet SR

Common side effects:

Dizziness
Drowsiness
Dry mouth
Weight gain
Swelling in the hands or feet

Serious side effects:

Allergic reactions
Suicidal thoughts
Mood changes
Rare muscle problems

Precautions of Cuprega 75mg Tablet SR

Before taking Cuprega 75mg Tablet SR, it is important to consider certain precautions. Use with caution if you have a history of substance abuse, as Pregabalin can be habit-forming. It is contraindicated in individuals with severe kidney problems. Pregnant or breastfeeding women should consult a doctor before use.

How to Take Cuprega 75mg Tablet SR

Take the tablet orally, with or without food.
The starting dose is usually 150 mg per day, taken in two doses of 75 mg each.
The dose may be increased to 300 mg per day after one week, taken in two doses of 150 mg each.
The maximum dose is 600 mg per day.

Conclusion of Cuprega 75mg Tablet SR

Cuprega 75mg Tablet SR is a valuable medication for managing pain and anxiety-related conditions. By understanding its uses, side effects, and precautions, patients can effectively incorporate it into their treatment plan under the guidance of a healthcare professional.